$-0.08
(Market cap
$26 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.3
-
Face value
--
-
Shares outstanding
9,979,298
10 Years Aggregate
CFO
$-124.31 Mln
EBITDA
$-158.28 Mln
Net Profit
$-171.58 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
| -71.7 | 14.3 | -52.1 | -78.1 | -41.3 | -45.7 | -42.4 |
|
BSE Sensex*
| -8.9 | -1.2 | 3.2 | -3.3 | 6.0 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
| -37.5 | 7.2 | 66.5 | -66.9 | 68.4 | -39.5 | 53.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Atossa Genetics Inc (ATOS)
|
2.5 | 25.8 | 0.0 | -37.7 | -- | -114 | -- | 1.0 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Atossa Genetics Inc (ATOS)
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor... modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. Read more
-
Chairman, CEO & President
Dr. Steven C. Quay FCAP, M.D., Ph.D.
-
Chairman, CEO & President
Dr. Steven C. Quay FCAP, M.D., Ph.D.
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Atossa Genetics Inc (ATOS)
What is the current share price of Atossa Genetics Inc (ATOS) Today?
The share price of Atossa Genetics Inc (ATOS) is $2.50 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Atossa Genetics Inc (ATOS) has given a return of -41.33% in the last 3 years.
What is the current PB & PE ratio of Atossa Genetics Inc (ATOS)?
Since, TTM earnings of Atossa Genetics Inc (ATOS) is negative, P/E ratio is not available.
The P/B ratio of Atossa Genetics Inc (ATOS) is 0.98 times as on 28-Aug-2026, a 81 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.15 |
0.13 |
2024 |
-0.31 |
0.11 |
2023 |
-3.66 |
1.21 |
2022 |
-0.17 |
0.04 |
2021 |
-0.66 |
0.10 |
What is the 52 Week High and Low of Atossa Genetics Inc (ATOS)?
The 52-week high and low of Atossa Genetics Inc (ATOS) are Rs 19.35 and Rs 1.70 as of 01-Sep-2026.
What is the market cap of Atossa Genetics Inc (ATOS)?
Atossa Genetics Inc (ATOS) has a market capitalisation of $ 26 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Atossa Genetics Inc (ATOS)?
Before investing in Atossa Genetics Inc (ATOS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.